Literature DB >> 20053995

Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2.

Isabelle Broutin1, Jean-Baptiste Jomain, Estelle Tallet, Jan van Agthoven, Bertrand Raynal, Sylviane Hoos, Birthe B Kragelund, Paul A Kelly, Arnaud Ducruix, Patrick England, Vincent Goffin.   

Abstract

We report the first crystal structure of a 1:2 hormone.receptor complex that involves prolactin (PRL) as the ligand, at 3.8-A resolution. Stable ternary complexes were obtained by generating affinity-matured PRL variants harboring an N-terminal tail from ovine placental lactogen, a closely related PRL receptor (PRLR) ligand. This structure allows one to draw up an exhaustive inventory of the residues involved at the PRL.PRLR site 2 interface, consistent with all previously reported site-directed mutagenesis data. We propose, with this description, an interaction model involving three structural components of PRL site 2 ("three-pin plug"): the conserved glycine 129 of helix alpha3, the hydrogen bond network involving surrounding residues (glycine cavity), and the N terminus. The model provides a molecular basis for the properties of the different PRL analogs designed to date, including PRLR antagonists. Finally, comparison of our 1:2 PRL.PRLR(2) structure with those of free PRL and its 1:1 complex indicates that the structure of PRL undergoes significant changes when binding the first, but not the second receptor. This suggests that the second PRLR moiety adapts to the 1:1 complex rather than the opposite. In conclusion, this structure will be a useful guiding tool for further investigations of the molecular mechanisms involved in PRLR dimerization and activation, as well as for the optimization of PRLR antagonists, an emerging class of compounds with high therapeutic potential against breast and prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053995      PMCID: PMC2832991          DOI: 10.1074/jbc.M109.089128

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Rational design of potent antagonists to the human growth hormone receptor.

Authors:  G Fuh; B C Cunningham; R Fukunaga; S Nagata; D V Goeddel; J A Wells
Journal:  Science       Date:  1992-06-19       Impact factor: 47.728

2.  Model for growth hormone receptor activation based on subunit rotation within a receptor dimer.

Authors:  Richard J Brown; Julian J Adams; Rebecca A Pelekanos; Yu Wan; William J McKinstry; Kathryn Palethorpe; Ruth M Seeber; Thea A Monks; Karin A Eidne; Michael W Parker; Michael J Waters
Journal:  Nat Struct Mol Biol       Date:  2005-08-21       Impact factor: 15.369

Review 3.  Structural features of prolactins and growth hormones that can be related to their biological properties.

Authors:  C S Nicoll; G L Mayer; S M Russell
Journal:  Endocr Rev       Date:  1986-05       Impact factor: 19.871

Review 4.  Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

Authors:  J J Kopchick; C Parkinson; E C Stevens; P J Trainer
Journal:  Endocr Rev       Date:  2002-10       Impact factor: 19.871

Review 5.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

6.  Structure and function of a new class of human prolactin antagonists.

Authors:  Laura DePalatis; Colleen M Almgren; Jypji Patmastan; Mark Troyer; Todd Woodrich; Charles L Brooks
Journal:  Protein Expr Purif       Date:  2009-02-21       Impact factor: 1.650

7.  Structural and thermodynamic bases for the design of pure prolactin receptor antagonists: X-ray structure of Del1-9-G129R-hPRL.

Authors:  Jean-Baptiste Jomain; Estelle Tallet; Isabelle Broutin; Sylviane Hoos; Jan van Agthoven; Arnaud Ducruix; Paul A Kelly; Birthe B Kragelund; Patrick England; Vincent Goffin
Journal:  J Biol Chem       Date:  2007-09-04       Impact factor: 5.157

8.  The N-terminus of human prolactin modulates its biological properties.

Authors:  Sophie Bernichtein; Jean-Baptiste Jomain; Paul A Kelly; Vincent Goffin
Journal:  Mol Cell Endocrinol       Date:  2003-10-31       Impact factor: 4.102

9.  Case-controlled structure validation.

Authors:  Randy J Read; Gerard J Kleywegt
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-01-20

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  18 in total

1.  Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R).

Authors:  Yue Zhang; Sajina Gc; Sweta B Patel; Ying Liu; Andrew J Paterson; John C Kappes; Jing Jiang; Stuart J Frank
Journal:  Mol Cell Endocrinol       Date:  2019-05-14       Impact factor: 4.102

2.  In silico prediction of prolactin molecules as a tool for equine genomics reproduction.

Authors:  A Neis; F S Kremer; L S Pinto; P M M Leon
Journal:  Mol Divers       Date:  2019-02-10       Impact factor: 2.943

3.  A Residue Quartet in the Extracellular Domain of the Prolactin Receptor Selectively Controls Mitogen-activated Protein Kinase Signaling.

Authors:  Chi Zhang; Mads Nygaard; Gitte W Haxholm; Florence Boutillon; Marie Bernadet; Sylviane Hoos; Patrick England; Isabelle Broutin; Birthe B Kragelund; Vincent Goffin
Journal:  J Biol Chem       Date:  2015-03-17       Impact factor: 5.157

4.  Prolactin Signaling Stimulates Invasion via Na(+)/H(+) Exchanger NHE1 in T47D Human Breast Cancer Cells.

Authors:  Elena Pedraz-Cuesta; Jacob Fredsted; Helene H Jensen; Annika Bornebusch; Lene N Nejsum; Birthe B Kragelund; Stine F Pedersen
Journal:  Mol Endocrinol       Date:  2016-05-13

5.  Two independent histidines, one in human prolactin and one in its receptor, are critical for pH-dependent receptor recognition and activation.

Authors:  Mandar V Kulkarni; M Cristina Tettamanzi; James W Murphy; Camille Keeler; David G Myszka; Naomi E Chayen; Elias J Lolis; Michael E Hodsdon
Journal:  J Biol Chem       Date:  2010-09-30       Impact factor: 5.157

Review 6.  Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.

Authors:  Eric M Jacobson; Eric R Hugo; Traci R Tuttle; Ruben Papoian; Nira Ben-Jonathan
Journal:  Trends Endocrinol Metab       Date:  2010-09-16       Impact factor: 12.015

7.  A Miniature Protein Stabilized by a Cation-π Interaction Network.

Authors:  Timothy W Craven; Min-Kyu Cho; Nathaniel J Traaseth; Richard Bonneau; Kent Kirshenbaum
Journal:  J Am Chem Soc       Date:  2016-01-26       Impact factor: 15.419

8.  Subdomain 2, Not the Transmembrane Domain, Determines the Dimerization Partner of Growth Hormone Receptor and Prolactin Receptor.

Authors:  Ying Liu; Jing Jiang; Bradford Lepik; Yue Zhang; Kurt R Zinn; Stuart J Frank
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

Review 9.  Molecular mechanisms of prolactin and its receptor.

Authors:  Charles L Brooks
Journal:  Endocr Rev       Date:  2012-05-10       Impact factor: 19.871

10.  Mutant prolactin receptor and familial hyperprolactinemia.

Authors:  Paul J Newey; Caroline M Gorvin; Stephen J Cleland; Christian B Willberg; Marcus Bridge; Mohammed Azharuddin; Russell S Drummond; P Anton van der Merwe; Paul Klenerman; Chas Bountra; Rajesh V Thakker
Journal:  N Engl J Med       Date:  2013-11-06       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.